Compare BLMN & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLMN | YDES |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 674.3M | 543.0M |
| IPO Year | 2012 | 2024 |
| Metric | BLMN | YDES |
|---|---|---|
| Price | $7.87 | $6.91 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $7.88 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 701.4K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.99% | N/A |
| EPS Growth | ★ 106.71 | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $4,213,346,000.00 | N/A |
| Revenue This Year | $2.07 | N/A |
| Revenue Next Year | $1.81 | N/A |
| P/E Ratio | $7.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.19 | $1.70 |
| 52 Week High | $12.63 | $22.00 |
| Indicator | BLMN | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 74.07 |
| Support Level | $7.79 | $1.99 |
| Resistance Level | $8.74 | $9.11 |
| Average True Range (ATR) | 0.44 | 0.82 |
| MACD | -0.07 | 0.26 |
| Stochastic Oscillator | 10.35 | 95.52 |
Bloomin Brands Inc is a casual dining restaurant company, with a portfolio of, differentiated restaurant concepts. Its restaurant portfolio includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill and Fleming's Prime Steakhouse & Wine Bar. Its restaurant concepts range in price point and degree of formality from casual (Outback Steakhouse and Carrabba's Italian Grill) to polished casual (Bonefish Grill) and fine dining (Fleming's Prime Steakhouse & Wine Bar). The U.S. segment includes all restaurants operating in the U.S. while franchised restaurants operating outside the U.S. are included in the international franchise segment.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.